Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.46 | N/A | -12.63% |
management commentary, guidance changes, and full analysis available with Pro.
| -12.63% |
Tone: Defensive
Management expressed concerns about current market conditions impacting performance. They reiterated their commitment to innovation and pipeline development.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term strategies despite short-term setbacks.
Bristol Myers Squibb's earnings report showed a significant miss on EPS, which contributed to a 5.81% decline in stock price. Investors may be concerned about the company's current challenges and lack of guidance. The management's defensive tone suggests that they are aware of the hurdles ahead but remain focused on long-term growth strategies.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERIS BANCORP
Jul 28, 2025